Additionally, the lower rate of minor/nuisance bleeding reported with FXI inhibition could have resulted in better treatment compliance in patients assigned to FXI inhibitor than those taking DOAC, leading to lower risk of venous thromboembolism. Here, F11 is linked to venous thromboembolism.